Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vivos Therapeutics

2.52
+0.22009.57%
Post-market: 2.650.1300+5.16%19:58 EDT
Volume:96.97K
Turnover:239.66K
Market Cap:14.84M
PE:-1.14
High:2.53
Open:2.36
Low:2.35
Close:2.30
Loading ...

New Strong Buy Stocks for January 8th

Zacks
·
08 Jan

After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar

Simply Wall St.
·
27 Dec 2024

Vivos Therapeutics Launches $3.5 Million Registered Direct Offering

MT Newswires Live
·
23 Dec 2024

Vivos to sell 709,220 shares at $4.935 in registered direct offering

TIPRANKS
·
23 Dec 2024

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
23 Dec 2024

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
23 Dec 2024

All You Need to Know About Vivos Therapeutics (VVOS) Rating Upgrade to Buy

Zacks
·
19 Dec 2024

Vivos Therapeutics Is Maintained at Buy by Alliance Global Partners

Dow Jones
·
20 Nov 2024

Vivos Therapeutics Inc : Alliance Global Partners Cuts Target Price to $6 From $8.25

THOMSON REUTERS
·
19 Nov 2024

Vivos Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
17 Nov 2024

Vivos Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Vivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

GuruFocus.com
·
15 Nov 2024

Vivos Therapeutics Reports Revenue Growth and Strategic Milestones

TIPRANKS
·
15 Nov 2024

Vivos Therapeutics Q3 2024 GAAP EPS $(0.40) Beats $(0.79) Estimate, Sales $3.860M Miss $4.061M Estimate

Benzinga
·
15 Nov 2024

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

THOMSON REUTERS
·
15 Nov 2024

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

GlobeNewswire
·
15 Nov 2024

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

GlobeNewswire
·
14 Nov 2024

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Simply Wall St.
·
12 Nov 2024

Vivos Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview

Reuters
·
09 Nov 2024